Letter to the Editor

*Helicobacter pylori* and Colorectal Cancer Risk—Letter

Jannis Kountouras, Nikolaos Kapetanakis, Christos Zavos, Stergios A. Polyzos, Elisabeth Vardaka, Panagiotis Katsinelos, Iordanis Romiopoulos, Kyriaki Anastasiadou, Nikolaos Giorgakis, Christina Nikolaidou, and Ioannis Venizelos

Epplen and colleagues (1) reported that the overall *Helicobacter pylori* (H. pylori) seropositivity was not associated with colorectal cancer risk, and seropositivity to specific *H. pylori* proteins, particularly the toxin VacA antibodies, may be associated with a higher risk of colorectal cancer and right-sided colon cancers.

Remarkably, the serologic test does not discriminate between current and past infections and, apart from past infections that may even be more relevant for oncogenesis, such a distinction is essential because only current *H. pylori* infection (Hp-I) induces humoral and cellular immune responses that produce or perpetuate chronic inflammatory processes in gastrointestinal tract with potential oncogenic sequelae; many neoplasms including colorectal neoplasms arise at the sites of chronic inflammation and infection (2, 3).

On the basis of histology for documentation of current *Hp-I*, our series in 50 patients with colorectal cancer, 25 patients with colorectal adenomas, and 10 controls showed significantly higher *Hp-I* presence in colorectal adenomas (68%) and colorectal cancer (84%) groups than controls (30%; ref. 4). Remarkably, *H. pylori* presence was documented by immunohistochemical stain in colorectal adenomas and colorectal cancer tissues (4, 5).

Presence of *Hp-I* with accompanying immunohistochemical expression of CD44 [indicator of cancer stem cells (CSC) and/or bone marrow–derived stem cells (BMDSC)] in biopsy specimens was found in a high proportion of patients with colorectal adenomas accompanied with moderate/severe dysplasia (88%) and patients with colorectal cancer with moderate/severe degree of malignancy (91%). Comparable pictures were also obtained for proliferation marker Ki-67, antiapoptotic Bcl-2, and CD45 (assessing mainly T and B lymphocytes locally) immunohistochemical expressions (4, 5); these mediators might also serve as a risk *H. pylori* biomarkers involved in the sequence: normal colon epithelium–colorectal adenomas–colorectal cancer development/progression.

Considering the mechanisms underlying the *Hp-I* involvement in the aforementioned sequence, apart from the left colon–limited oncogenic actions of *Hp*-induced gastrin, also mentioned by Epplen and colleagues (1), our studies indicate that *Hp-I* may be involved in colon carcinogenesis by: (i) inducing a possible chronic inflammatory mucosal damage, comparable with upper gastrointestinal tract (UGT); (ii) stimulating CSCs or recruiting BMDSCs, similar to UGT *Hp-I*-associated chronic inflammation, metaplasia, dysplasia, and BMDSCs recruitment that may facilitate tumor formation/progression in animal models and humans; (iii) and affecting oncogenes and immune surveillance processes (4, 5).

Finally, the following concept about the VacA antibody association with right-sided colon cancers observed by Epplen and colleagues (1) might be considered: (i) as right-sided colon cancers have higher distant metastases than left-sided colon cancers, circulation of activated monocytes (possibly infected with *H. pylori* due to defective autophagy) might lead to potential *H. pylori*-related metastatic disease (6); and (ii) VacA promotes *H. pylori* intracellular survival and modulates host immune responses.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

Received September 30, 2013; accepted October 28, 2013; published OnlineFirst November 27, 2013.

**References**


Helicobacter pylori and Colorectal Cancer Risk—Letter

Jannis Kountouras, Nikolaos Kapetanakis, Christos Zavos, et al.


Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-13-1008

This article cites 6 articles, 2 of which you can access for free at:
http://cebp.aacrjournals.org/content/23/2/365.full.html#ref-list-1

This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/23/2/365.full.html#related-urls

Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.